hypertrophic cardiomyopathy 13
MeSH: C567686ORPHA: 1552 Treatments Available
Overview
hypertrophic cardiomyopathy that has material basis in heterozygous mutation in the TNNC1 gene on chromosome 3p21
Available Treatments (2)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| mavacamten Orphan | oral capsule, 2.5mg, 5mg, 10mg, 15mg | FDA Approved | 9 | 14d |
| disopyramide | oral capsule, 100mg, 150mg; extended-release capsule, 100mg, 150mg | FDA Approved | 7 | 7d |
Classification & Codes
MeSH Code
C567686Orphanet Code
ORPHA:155hypertrophic cardiomyopathy 13
| MeSH | C567686 |
| Orphanet | ORPHA:155 |
| Treatments | 2 drug(s) |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO